FDA Approves Talon’s Marqibo To Treat Rare Type of Leukemia

The Food and Drug Administration Aug. 9 approved Marqibo (vincristine sulfate liposome injection) to treat adults with a rare type of leukemia called Philadelphia chromosome negative (Ph-) acute lymphoblastic leukemia (ALL).

ALL is a rapidly progressing form of blood and bone marrow cancer that is more commonly diagnosed in children than adults, the agency said.

Marqibo, which is marketed by South San Francisco-based Talon Therapeutics Inc., is approved for patients whose leukemia has returned two or more times, or whose leukemia has progressed following two or more regimens of anti-leukemia therapy. Marqibo contains vincristine, a commonly used anti-cancer drug, encased ...